menu
    • menu
    [{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Westat","sponsor":"US Department of Defense | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Nephrology","graph2":"Phase II","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Westat \/ US Department of Defense | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Westat \/ US Department of Defense | Clinipace Worldwide"},{"orgOrder":0,"company":"Centre d'Etude des Cellules Souches","sponsor":"Genethon","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Centre d'Etude des Cellules Souches","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre d'Etude des Cellules Souches \/ Genethon","highestDevelopmentStatusID":"8","companyTruncated":"Centre d'Etude des Cellules Souches \/ Genethon"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerebral Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cerebral Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cereno Scientific \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Depakote

    Menu

    Depakote

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Ap...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 26, 2010

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Conditio...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 26, 2010

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alembic Pharmaceuticals Limited

                            India arrow
                            CPhI Korea
                            Not Confirmed

                            Alembic Pharmaceuticals Limited

                            India arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Pharma Gets USFDA Nod for Seizure Treatment Drug

                            Details : Divalproex sodium is an GABA stimulating, anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures.

                            Product Name : Depakote Sprinkle-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cereno Scientific

                            Sweden arrow
                            CPhI Korea
                            Not Confirmed

                            Cereno Scientific

                            Sweden arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium,Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial

                            Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : Divalproex Sodium,Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cereno Scientific

                            Sweden arrow
                            CPhI Korea
                            Not Confirmed

                            Cereno Scientific

                            Sweden arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cereno Scientific Obtains IND Acceptance from FDA to Start Phase II Study with Drug Candidate CS1 in PAH

                            Details : CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2021

                            Lead Product(s) : Divalproex Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth